Concentrated PEI Formulations Retain Biological Efficacy Following Long-Term Storage at 4°C. (2010)

Davies, L. A., Nunez-Alonso, G. A., Hyde, S. C. & Gill, D. R.

Molecular Therapy, 18, S123

Download   Back

Aerosol delivery of gene transfer agents is likely to be the most practical route for routine vector administration to the lung. When complexed with plasmid DNA (pDNA), the cationic polymer, 25kDa branched polyethyleneimine (PEI) retains transfection efficiency following aerosolisation and consequently is a popular choice for lung gene transfer. Until recently, progress towards the clinical use of PEI was limited by the low pDNA concentration achievable in standard PEI formulations. However, we have shown that concentrated PEI (cPEI) formulations containing up to 8 mg/ml pDNA can be prepared by controlled ultrafiltration of pDNA/PEI complexes, leading to robust levels of gene expression in the lungs of mice and sheep following aerosol delivery. We have capitalised on this important development to further exploit the potential of cPEI aerosol delivery for use in the clinic, focusing on formulations that are physically stable and suitable for long-term storage following manufacture, an absolute requirement for clinical utility. Plasmid DNA encoding firefly luciferase reporter gene was complexed with branched 25kDa PEI (N:P of 10:1) at an initial pDNA concentration of 0.2 mg/ml in sterile water and concentrated to 2.0 ± 0.2 mg/ml using a pressurised ultrafiltration cell incorporating a 100kDa cut-off cellulose membrane. Complexes were filter sterilised and aliquots stored under nitrogen in glass vials at 4 ± 2 ?C for 0, 1, 2, 4, 8, or 21 weeks. Visual inspection revealed no evidence of aggregation or precipitation at any time-point. A small increase in particle size from 62.5 ± 0.3 nm (mean ± SEM) at 0 weeks to 65.1 ± 0.3 nm at 21 weeks (p<0.05 ANOVA) was identified using dynamic light scattering. No significant deviations from the initial particle zeta potential (+ 62.8 ± 0.5 mV) were observed over the same period. Following storage, cPEI complexes were aerosolised to the lungs of BALB/c mice via whole body aerosol exposure and 24 hrs later luciferase expression was measured in lung homogenates at 426 ± 32 RLU/mg protein compared to 0.05 ± 0.01 RLU/mg in untreated mice (p < 0.0001, Student's t-test). Storage of cPEI formulations for 1 week was associated with a small reduction in luciferase expression (307 ± 37 RLU/mg), but no further loss of biological efficacy was observed upon continued storage, with equivalent expression levels observed after 21 weeks of storage (p>0.05 ANOVA & Tukey's multiple comparison test). In conclusion, we have utilised physical characterisation and in vivo expression studies to investigate the stability of cPEI complexes, demonstrating that pDNA/cPEI formulations prepared by ultrafiltration are stable and can be stored for extended periods at +4?C with minimal loss of biological efficacy. This provides further evidence to support the potential of cPEI for clinical applications.

Introductory Videos
Medical Futures Innovation Award 2011
Twitter Feed
About Us
Contact Us
Lab Events
Environemental Policy
About this Site

Google Site Search

Site Feedback Form

All Site Images



How the Consortium works/FAQs

Consortium Website

Centre for Molecular Medicine, Edinburgh
The Roslin Institute
Dep of Gene Therapy, Imperial



The Run-in Study

Single Dose Clinical Trial

Multi Dose Clinical Trial


Our Research

Non-viral Vector Development

Aerosol Mediated Gene Delivery

Viral Vector Development

Taqman Core Facility

Cystic Fibrosis

History of CF

Discovery of the CFTR Gene

CFTR Protein Structure

CFTR Function

CF Links


Gene Therapy

Introduction to Gene Therapy

Other CF Gene Therapy Groups

Why use Gene Therapy for CF

Target Cells for CF Gene Therapy

Barriers for CF Gene Therapy

Clinical Trials

Gene Therapy Successes

Gene Therapy Links




Papers in Journals

Conference Posters & Presentations

Book Chapters

D.Phil Theses



Gene Therapy Seminars


Directions & Venue